Sign In
Buy CARA
$5.32
+0 (+0%)
At Close: Jul 14, 2025
Cara Therapeutics, Inc. (CARA) CEO Chris Posner on Q1 2022 Results - Earnings Call Transcript
06:20pm, Monday, 09'th May 2022
Cara Therapeutics, Inc. (NASDAQ:CARA ) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Iris Francesconi - Interim Head, Investor Relations Chris Posner - President & Chief
Vericel Corporation (VCEL) Reports Q1 Loss, Tops Revenue Estimates
01:05pm, Wednesday, 04'th May 2022 Zacks Investment Research
Vericel Corporation (VCEL) delivered earnings and revenue surprises of 0% and 6.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Cara Therapeutics to Present at May Investor Conferences
04:01pm, Tuesday, 03'rd May 2022
STAMFORD, Conn., May 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of
Cara Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022
11:00am, Friday, 29'th Apr 2022 GlobeNewswire Inc.
STAMFORD, Conn., April 29, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives
Cara Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022
07:00am, Friday, 29'th Apr 2022
STAMFORD, Conn., April 29, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives o
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
12:52pm, Thursday, 28'th Apr 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Moderna Seeks FDA Emergency Use Nod For COVID-19 Shot In Kids 2-6
Moderna Inc (NASDAQ: MRNA) submitt
Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients
05:00am, Thursday, 28'th Apr 2022 GlobeNewswire Inc.
ST. GALLEN, Switzerland and STAMFORD, Conn., April 28, 2022 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that t
UnitedHealth (UNH) to Post Q1 Earnings: What to Expect
02:16pm, Monday, 11'th Apr 2022 Zacks Investment Research
UnitedHealth Group's (UNH) first-quarter results are likely to reflect the benefits of improving premiums and products.
Cara Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
11:00am, Tuesday, 05'th Apr 2022 GlobeNewswire Inc.
STAMFORD, Conn., April 05, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives
Cara Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
07:00am, Tuesday, 05'th Apr 2022
STAMFORD, Conn., April 05, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives o
Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Improves Itch and Inflammatory Biomarkers in Atopic Dermatitis Patients with Moderate-To-Severe Pruritus
11:00am, Monday, 28'th Mar 2022 GlobeNewswire Inc.
Data presented in late-breaking session at the 2022 American Academy of Dermatology (AAD) Annual Meeting Data presented in late-breaking session at the 2022 American Academy of Dermatology (AAD) Annua
Cara price target lowered at H.C. Wainwright on pricing for pruritus drug (NASDAQ:CARA)
08:04pm, Monday, 14'th Mar 2022 Seeking Alpha
Flagging potential pricing issues for the company’s pruritus therapy, Korsuva, H.C
Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Data Selected for Late-Breaking Presentation at 2022 American Academy of Dermatology Annual Meeting
09:01pm, Tuesday, 08'th Mar 2022 GlobeNewswire Inc.
Oral presentation will include biomarker data from KARE Phase 2 clinical trial of Oral KORSUVA™ (difelikefalin) for the treatment of moderate-to-severe pruritus in atopic dermatitis patients
Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Data Selected for Late-Breaking Presentation at 2022 American Academy of Dermatology Annual Meeting
09:01pm, Tuesday, 08'th Mar 2022 GlobeNewswire
Oral presentation will include biomarker data from KARE Phase 2 clinical trial of Oral KORSUVA™ (difelikefalin) for the treatment of moderate-to-severe pruritus in atopic dermatitis patients
Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2022
03:04pm, Tuesday, 08'th Mar 2022 Benzinga
Upgrades
According to Janney Montgomery Scott, the prior rating for Wintrust Financial Corp (NASDAQ:WTFC) was changed from Neutral to Buy. Wintrust Finl earned $1.58 in the fourth quarter, compared to
